Sep 2024 $14 M No. 6 $10 to $50 million 10
Spine BioPharma, LLC: Raise no. 6, Sep 2024 × Investors in this round 10 investors had bought by the notice of Dec 18, 2024: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $14 M of $24 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fran R. Magee · Executive Officer · Chief Technology Officer Jason J. Gallagher · Executive Officer · Chief Commercial Officer/Chief Operations Officer Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer Frank R. Cammisa, MD · Director John J. Viscogliosi · Director Thomas R. Bumol, PhD · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Offering is Convertible Notes.”Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 18, 2024. Read the notice at the SEC .
equity, debt SEC Oct 2023 $2 M No. 5 $2 to $10 million 3
Spine BioPharma, LLC: Raise no. 5, Oct 2023 × Investors in this round 3 investors had bought by the notice of Oct 11, 2023: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $15 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer Frank R. Cammisa, MD · Director John J. Viscogliosi · Director Thomas R. Bumol, PhD · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Offering is Convertible Notes.”Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 11, 2023. Read the notice at the SEC .
equity, debt SEC Aug 2023 $2 M No. 4 Under $2 million 1
Spine BioPharma, LLC: Raise no. 4, Aug 2023 × Investors in this round 1 investor had bought by the notice of Aug 31, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $13 M offered; $11 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer Frank R. Cammisa, MD · Director John J. Viscogliosi · Director Thomas R. Bumol, PhD · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Offering is Class B Preferred Stock.”Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 31, 2023. Read the notice at the SEC .
equity SEC Mar 2022 $13 M No. 3 $10 to $50 million 6
Spine BioPharma, LLC: Raise no. 3, Mar 2022 × Investors in this round 6 investors had bought by the notice of Mar 24, 2022: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $30 M offered; $17 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer Frank R. Cammisa, MD · Director John J. Viscogliosi · Director Thomas R. Bumol, PhD · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Offering is Class B Preferred Stock.”Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 24, 2022. Read the notice at the SEC .
equity SEC Apr 2021 $3 M No. 2 $2 to $10 million 1
Spine BioPharma, LLC: Raise no. 2, Apr 2021 × Investors in this round 1 investor had bought by the notice of Apr 20, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Delaware People named in the notice John J Viscogliosi · Executive Officer · Manager of the Issuer LLC J Viscogliosi Brothers, · Executive Officer · Member of the Issuer Marc R. Viscogliosi · Executive Officer · Manager and Chief Executive Officer of the Issuer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Marc R. Viscogliosi, Manager and Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Apr 20, 2021. Read the notice at the SEC .
equity, debt, options SEC Mar 2021 $5 M No. 1 $2 to $10 million 14
Spine BioPharma, LLC: Raise no. 1, Mar 2021 × Investors in this round 14 investors had bought by the notice of Mar 22, 2021: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken $25,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Delaware People named in the notice John J Viscogliosi · Executive Officer · Manager of the Issuer LLC J Viscogliosi Brothers, · Executive Officer · Member of the Issuer Marc R. Viscogliosi · Executive Officer · Manager and Chief Executive Officer of the Issuer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The offering is of Class A Preferred Units”Signed by Marc R. Viscogliosi, Manager and Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Mar 22, 2021. Read the notice at the SEC .
equity SEC